ERBB2 and breast cancer: HER2-targeted therapies have improved survival in HER2-positive breast cancer, and recent data suggest potential benefits for patients with HER2-low tumors (defined as immunohistochemistry (IHC) 1 + or 2 + and, in situ hybridization (ISH)-negative).